US OptionsDetailed Quotes
ARCT241220C20000
- 0.03
- 0.000.00%
15min DelayTrading Dec 20 16:00 ET
0.00High0.00Low
0.00Open0.03Pre Close0 Volume2.16K Open Interest20.00Strike Price0.00Turnover0.00%IV19.58%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-10DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma558.33Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Arcturus Therapeutics Stock Discussion
Sign in to post a comment
$Arcturus Therapeutics (ARCT.US)$ this company is associated with Bill and Melinda Gates Foundation. they are in the process of developing a bird flu vaccination. the vaccine they're calling a pandemic injection.
out of California within the past couple of weeks you have Governor New scum talking about bird flu.. I've heard it mentioned on a couple of the fake news stations this past week. and now the self-proclaimed expert in medicine who believes that the world must be depopulated by 90% but i...
out of California within the past couple of weeks you have Governor New scum talking about bird flu.. I've heard it mentioned on a couple of the fake news stations this past week. and now the self-proclaimed expert in medicine who believes that the world must be depopulated by 90% but i...
7
19
2
$Arcturus Therapeutics (ARCT.US)$ wtf is happening bout to put this hoe down
1
Analysts maintain loss per share estimates for next year with no major changes to revenue estimates. However, the company's performance is expected to underperform the wider industry. The steady consensus price target indicates that reduced loss estimates may not positively impact the stock's long-term valuation.
Despite Arcturus Therapeutics Holdings Inc.'s strong run, its P/S ratio remains low due to a weak revenue outlook. Investors believe the potential for revenue improvement doesn't justify a higher P/S ratio, forming a barrier for the share price.
The recent improvement in total shareholder return could indicate that the business is getting better over time. However, there are 2 warning signs that investors should be aware of. The sentiment around the company seems to be positive lately.
No comment yet
10baggerbamm OP : as a follow-up this is where you use options because you know exactly the risk going in you know what your loss is going to be.
unfortunately June of 25 is as far out as the contracts go. buying it out of the money contract and throwing a bid in which there's zero bid is what I'm going to do.. so I'll throw different bids in for a nickel $0, .10, .20 different amounts of contracts.. and see if I get filled
unfortunately June of 25 is as far out as the contracts go. buying it out of the money contract and throwing a bid in which there's zero bid is what I'm going to do.. so I'll throw different bids in for a nickel $0, .10, .20 different amounts of contracts.. and see if I get filled
10baggerbamm OP : additionally if you look at transactions in December you have acquisitions of stock by four parties within the company three are 60,000 shares one is 190,000 shares.
as they say people sell stock for variety of reasons but they buy stock for only one.
as they say people sell stock for variety of reasons but they buy stock for only one.
10baggerbamm OP : 11/11/2024 - 04:01 PM
SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a “Study Can Proceed” notification for the Company’s Investigational New Drug (IND) application, ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The clinical study is funded by Biomedical Advanced Research and Development Authority (BARDA) and designed to enroll approximately 200 healthy adults in the United States.
SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a “Study Can Proceed” notification for the Company’s Investigational New Drug (IND) application, ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The clinical study is funded by Biomedical Advanced Research and Development Authority (BARDA) and designed to enroll approximately 200 healthy adults in the United States.
10baggerbamm OP :
10baggerbamm OP : https://expose-news.com/2024/12/18/self-replicating-vaccine-trial-in-the-usa/
View more comments...